Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

CagriSema is a weekly injection combining semaglutide, which is the active ingredient in Wegovy and mimics the gut hormone ...

Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...

CHICAGO — GLP-1, or Glucagon-like peptide-1, medications, similar to Ozemppic and Wegovy, are becoming more accessible, and ...

What new medicines are poised to take the leap from breakthrough to approval in 2025? Here’s what to expect this year.

(Wegovy is the version of semaglutide that’s available in the UK.) But tirzepatide (Mounjaro) has since been shown to pack more of a punch. “Semaglutide contains just one molecule, GLP-1 ...

In terms of its financial performance, Novo Nordisk's bread and butter are its therapies for type 2 diabetes (Ozempic) and obesity (Wegovy); both are the same molecule, semaglutide, which works by ...